- priority setting/ethics
- methods and metrics
- costing methods
- evidence synthesis
- test performance
- value of information
- microsimulation
- calibration/validation
- dynamic simulation
- approaches and applications
- decision analysis
- risk analysis
- benefit-cost analysis
- cost-effectiveness analysis
- technology assessment
- operations research
- chronic disease/risk
- global
- oceania
Resources Repository
-
ArticlePublication 2020Impact of Treatment and Imaging Modalities on 5-Year Net Survival of 11 Cancers in 200 Countries
This analysis describes the development of a microsimulation model of stage-specific cancer survival in 200 …
This analysis describes the development of a microsimulation model of stage-specific cancer survival in 200 countries/territories for 11 cancers (oesophagus, stomach, colon, rectum, anus, liver, pancreas, lung, breast, cervix uteri, and prostate). The paper estimated current 5-year net survival for diagnosed cancers in each country and potential survival gains from increasing the availability of individual treatment and imaging modalities, and more comprehensive packages of scale-up. Global 5-year net survival for all 11 cancers (combined) is…
Priority Setting/Ethics | Microsimulation | Calibration/Validation | Global | Chronic Disease/Risk | Health Outcomes | Health Systems -
ArticlePublication 2021Global Costs, Health Benefits, & Economic Benefits of Scaling Up Treatment and Imaging Modalities for Survival of 11 Cancers
This analysis estimated the costs and lifetime health and economic benefits of scaling up imaging …
This analysis estimated the costs and lifetime health and economic benefits of scaling up imaging and treatment modality packages on cancer survival in 200 countries/territories for patients diagnosed with one of 11 cancers (oesophagus, stomach, colon, rectum, anus, liver, pancreas, lung, breast, cervix uteri, and prostate). Using a microsimulation model of global cancer survival, the paper evaluated the costs and health and economic benefits of scaling up packages of treatment (chemotherapy, surgery, radiotherapy, and targeted…
Priority Setting/Ethics | Microsimulation | Benefit-Cost Analysis | Global | Chronic Disease/Risk | Health Outcomes | Health Systems -
Resource PackPublication, Teaching Resource 2020Resource Pack: Cost-Effectiveness of SSB Excise Taxes
The use of fiscal instruments, such as taxes or subsidies, to promote healthier dietary behavior …
The use of fiscal instruments, such as taxes or subsidies, to promote healthier dietary behavior has been of increasing interest in the last decade as the evidence-base builds for the health and economic consequences of obesity, overweight, and unhealthy eating. The motivation for using fiscal instruments in nutrition policy is to make the unhealthy option less affordable and less economically attractive by increasing the price via a tax, and therefore reduce the incentive to consume…
Evidence Synthesis | Microsimulation | Cost-Effectiveness Analysis | Oceania | Chronic Disease/Risk | Health Outcomes | Mathematical Models | Child/Nutrition | Policy/Regulation | Business/Industry | Economics/Finance | Food/Agriculture | Government/Law | Health/Medicine | North America | Latin America & Caribbean | Europe -
ArticlePublication 2017Extended Cost-Effectiveness Analyses of Cardiovascular Risk Factor Reduction Policies
This chapter summarizes lessons learned from three extended cost-effectiveness analyses (ECEAs) conducted on cardiovascular disease …
This chapter summarizes lessons learned from three extended cost-effectiveness analyses (ECEAs) conducted on cardiovascular disease (CVD) risk factor reduction policies, specifically highlighting new insights into the differential impacts of well-established CVD prevention interventions. Tobacco taxation, salt reduction, and primary prevention of CVD in high-risk individuals remain widely regarded as best buys in global noncommunicable disease policy, and the ECEAs confirm the findings of previous CEAs, namely, that these interventions will likely result in large health…
Evidence Synthesis | Priority Setting/Ethics | Cost-Effectiveness Analysis | Global | Chronic Disease/Risk | Health/Medicine -
BookPublication 2019Non-Communicable Disease Prevention: Best Buys, Wasted Buys, Contestable Buys
Non-communicable diseases (NCDs) are the leading cause of death worldwide, and the majority of these …
Non-communicable diseases (NCDs) are the leading cause of death worldwide, and the majority of these deaths occur in low- and middle-income countries. This book provides practical guidelines and lessons learned through real-world case studies. It is intended to be informative to NCD program managers, policy officers and decision-makers in low- and middle-income countries, who need to comparatively assess interventions for the prevention and control of NCDs.The authors emphasize the importance of context in NCD control…
Priority Setting/Ethics | Technology Assessment | Cost-Effectiveness Analysis | Global | Chronic Disease/Risk | Infectious Diseases | Health Systems | Policy/Regulation | Health/Medicine -
ReportPublication 2017DCP3: Cardiovascular, Respiratory, and Related Disorders
This report from the World Bank is the fifth volume of the Disease Control Priorities, …
This report from the World Bank is the fifth volume of the Disease Control Priorities, Third Edition (DCP3) series. It addresses the disease burden of cardiovascular, respiratory, and related disorders (CVRDs), which account for more than half of global adult deaths, mostly in low- and middle-income countries. While CVRDs are mostly preventable or can be treated to reduce morbidity, such interventions are costly and require greater capacity to detect and treat early. When combined with…
Evidence Synthesis | Cost-Effectiveness Analysis | Costing Methods | Global | Chronic Disease/Risk | Health Outcomes | Social Determinants | Health Systems | Global Governance | Climate/Environment | Health/Medicine -
ReportPublication 2015DCP3: Cancer
This report from the World Bank is the third volume of the Disease Control Priorities, …
This report from the World Bank is the third volume of the Disease Control Priorities, Third Edition (DCP3) series. It presents data on the complex patterns of cancer incidence and deaths globally, and offers evidence on effective measures to control cancers. This report identifies settings in which cancer treatment may be ineffective or wasteful, and offers alternative cancer care packages that are cost-effective and better suited to low-resource environments. The Disease Control Priorities Network (DCP)…
Evidence Synthesis | Cost-Effectiveness Analysis | Costing Methods | Global | Chronic Disease/Risk | Health Outcomes | Health Systems | Global Governance | Economics/Finance | Health/Medicine -
ArticlePublication 2017Cost-Effectiveness of Testing and Treatment for Latent TB
Testing for and treating latent tuberculosis infection (LTBI) is among the main strategies to achieve …
Testing for and treating latent tuberculosis infection (LTBI) is among the main strategies to achieve TB elimination in the United States. This analysis estimated health outcomes, costs, and cost-effectiveness of LTBI testing and treatment among non-US born residents with and without medical comorbidities (e.g., diabetes, HIV infection, and end-stage renal disease). A decision analytic tree and Markov cohort simulation model was used to compare the following strategies: no testing, tuberculin skin test (TST), interferon gamma release assay…
Microsimulation | Test Performance | Cost-Effectiveness Analysis | Global | Chronic Disease/Risk | State-Transition | Infectious Diseases | Health Systems | Economics/Finance | Health/Medicine | North America -
ArticlePublication 2017When Cost-Effective Interventions Are Unaffordable
Many health interventions deemed cost-effective are not affordable. Despite the importance of affordability to policymakers, …
Many health interventions deemed cost-effective are not affordable. Despite the importance of affordability to policymakers, little of the cost-effectiveness literature in global health addresses this issue. Budget impact analysis (BIA) describes an intervention's short-term costs and savings from the payer's perspective. This paper assesses the current use of budget impact analysis (BIA) and cost-effectiveness analysis (CEA) in health economic assessments conducted for low- and middle-income countries (LMICs). The authors recommend steps researchers and policymakers can…
Priority Setting/Ethics | Cost-Effectiveness Analysis | Costing Methods | Global | Chronic Disease/Risk | Infectious Diseases | Health Systems | Economics/Finance | Government/Law | Health/Medicine | Science/Technology